# Ansgar Schulz

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ansgar-schulz/

## Facts

| Field | Value |
| --- | --- |
| Citations | 14,578 |
| Field | Immunodeficiency and Autoimmune Disorders |
| h-index | 64 |
| i10-index | 171 |
| Last Known Institution | Universität Ulm |
| OpenAlex ID | https://openalex.org/A5021572787 |
| ORCID iD | 0000-0002-7798-7996 |
| Works | 668 |

## Researcher papers

- [Loss of the ClC-7 Chloride Channel Leads to Osteopetrosis in Mice and Man](https://scholariq.org/papers/loss-of-the-clc-7-chloride-channel-leads-to-osteopetrosis-in-mice-and-man/)
- [Osteopetrosis: genetics, treatment and new insights into osteoclast function](https://scholariq.org/papers/osteopetrosis-genetics-treatment-and-new-insights-into-osteoclast-function/)
- [Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99](https://scholariq.org/papers/long-term-survival-and-transplantation-of-haemopoietic-stem-cells-for/)
- [Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects](https://scholariq.org/papers/phenotype-penetrance-and-treatment-of-133-cytotoxic-t-lymphocyte-antigen-4/)
- [Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial](https://scholariq.org/papers/defibrotide-for-prophylaxis-of-hepatic-veno-occlusive-disease-in-paediatric/)
- [Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation](https://scholariq.org/papers/diagnosis-and-severity-criteria-for-sinusoidal-obstruction-syndrome-veno/)
- [Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study](https://scholariq.org/papers/long-term-follow-up-of-ipex-syndrome-patients-after-different-therapeutic/)
- [Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study](https://scholariq.org/papers/long-term-outcome-and-lineage-specific-chimerism-in-194-patients-with-wiskott/)
- [DOCK8 Deficiency: Clinical and Immunological Phenotype and Treatment Options - a Review of 136 Patients](https://scholariq.org/papers/dock8-deficiency-clinical-and-immunological-phenotype-and-treatment-options-a/)
- [Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation](https://scholariq.org/papers/long-term-outcome-following-hematopoietic-stem-cell-transplantation-in-wiskott/)
- [Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal](https://scholariq.org/papers/gene-therapy-for-infantile-malignant-osteopetrosis-review-of-pre-clinical/)

## Researcher topics

- [Immunodeficiency and Autoimmune Disorders](https://scholariq.org/topics/immunodeficiency-and-autoimmune-disorders/)
- [Hematopoietic Stem Cell Transplantation](https://scholariq.org/topics/hematopoietic-stem-cell-transplantation/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [Bone Metabolism and Diseases](https://scholariq.org/topics/bone-metabolism-and-diseases/)
- [Blood disorders and treatments](https://scholariq.org/topics/blood-disorders-and-treatments/)

## Researcher university

- [Universität Ulm](https://scholariq.org/institutions/universitat-ulm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.